Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Linear Formula:
(CH3)2C(SH)CH(NH2)CO2H
CAS Number:
Molecular Weight:
149.21
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1722375
Product Name
Penicillamine, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1
SMILES string
CC(C)(S)[C@@H](N)C(O)=O
InChI key
VVNCNSJFMMFHPL-VKHMYHEASA-N
grade
pharmaceutical primary standard
API family
penicillamine
manufacturer/tradename
EDQM
mp
210 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
Application
Penicillamine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
Storage Class
11 - Combustible Solids
wgk
WGK 2
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
J Karpinski et al.
American journal of nephrology, 17(6), 528-532 (1997-01-01)
Therapeutic use of D-penicillamine has been associated with a range of adverse effects. We present a patient with scleroderma, treated with D-penicillamine for 5 years, who developed severe renal failure due to rapidly progressive glomerulonephritis with both crescents and subepithelial
Y Gong et al.
Alimentary pharmacology & therapeutics, 24(11-12), 1535-1544 (2007-01-09)
D-Penicillamine is used for patients with primary biliary cirrhosis due to its ability to decrease hepatic copper and modulate the immune response. The results on effects of D--penicillamine in randomized-clinical trials of primary biliary cirrhosis patients are inconsistent. To systematically
A Boehler et al.
The European respiratory journal, 9(6), 1317-1319 (1996-06-01)
D-penicillamine-associated bronchiolitis obliterans (BO) is a rare but well-known pulmonary complication in patients with rheumatoid arthritis or progressive systemic sclerosis. It has been assumed that in most, if not all cases, BO is a complication of the underlying disease rather
[D-penicillamine nephropathy].
I Ohno
Ryoikibetsu shokogun shirizu, (16 Pt 1)(16 Pt 1), 523-525 (1997-01-01)
S L Klingenberg et al.
The Cochrane database of systematic reviews, (1)(1), CD004182-CD004182 (2006-01-27)
Primary sclerosing cholangitis is a cholestatic disease. D-penicillamine is suggested as a treatment option due to its copper reducing and immunomodulatory potential. To evaluate the beneficial and harmful effects of D-penicillamine for patients with primary sclerosing cholangitis. Eligible trials were
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service